Explore Business Standard
Bristol Myers Squibb (BMS) on Wednesday announced the launch of Kopozgo (Mavacamten), an oral, selective cardiac myosin inhibitor, in India. Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), BMS said in a statement. Mavacamten was approved by the Central Drugs Standard Control Organisation (CDSCO), with an import license issued on March 6, 2025. "Kopozgo is now available to patients in India. The approval of Kopozgo in India is based on positive efficacy and safety results from two Phase III clinical trials, EXPLORER-HCM and VALOR-HCM," the statement said. Sanjay Sharma, General Manager and Managing Director, BMS India, mentioned, "This breakthrough brings hope to individuals and families facing this condition, giving clinicians a novel therapy to address the unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular care fo
Over a third of India's children aged 5-9 could be having high triglycerides, with Jammu and Kashmir, West Bengal and northeastern states showing highest prevalence, according to a government report. Over 67 per cent of children in West Bengal, 64 per cent in Sikkim, 55 per cent in Nagaland, 57 per cent in Assam and 50 per cent in Jammu Kashmir were estimated to have high levels of triglycerides -- a type of blood fat that is known to increase risk of heart disease in later life. Kerala and Maharashtra were among the states showing lowest prevalence at 16.6 per cent and 19.1 per cent, respectively. 'Children in India 2025' -- the fourth edition since its start in 2008 -- was released by the Ministry of Statistics and Programme Implementation during the 29th Conference of Central and State Statistical Organisations (CoCSSO) on September 25 in Chandigarh. The report "provides a comprehensive and detailed analysis of the well-being of children in the country," the ministry said in a .
Pharma firm Caplin Point Laboratories Ltd on Wednesday said its arm Caplin Steriles Ltd has received final approval from the US health regulator for its generic milrinone lactate in 5 per cent dextrose injection indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) milrinone lactate in 5 per cent Dextrose Injection of strengths 20 mg/100 mL and 40 mg/200 mL in single-dose infusion bags, Caplin Point Laboratories said in a regulatory filing. The approved injection is a generic therapeutic equivalent version of the reference listed drug PRIMACOR in dextrose 5 per cent, by Sanofi Aventis US LLC, it added. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure, the company said. Citing IQVIA (IMS Health) data, the company said milrinone lactate in 5 per cent ...